*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and
*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. BiTE antibodies are showing promise as a potential new treatment option for those
Understand the EGFR mutation in lung cancer through this discussion between Dr. Natasha Leighl of Princess Margaret Hospital in Toronto
The EGFR Resisters hosted Dr. Josh Bauml for an extremely informative Facebook Live presentation on "Next Generation Sequencing for EGFR
*June 2019* Medscape. The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events)
*January 2019* Lung Cancer. This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and
*March 2019* Overview written by Donald Ox. This article deals with a case study of the latest clinical data of
*March 2019* This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the
*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for
*January 29, 2019* Lungevity, by Juhi Kunde. In 2004, after the discovery of mutations in the EGFR gene in lung
